Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457410 | 1.00 | EPHX1 (0.55) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL24817359 | 1.00 | EPHX1 (0.55) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL8273736 | 0.92 | USP30 (0.54) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL555950 | 0.92 | USP30 (0.54) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL13712552 | 0.91 | EPHX1 (0.55) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL438437 | 0.91 | EPHX1 (0.65) | EPHX1HDAC4ALDH1A1NPC1MAPT | |
| SCHEMBL30948838 | 0.88 | EPHX1 (0.57) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL15885465 | 0.88 | EPHX1 (0.46) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL29012284 | 0.87 | HSD11B1 (0.42) | EPHX1HSD11B1CYP2C9USP30HDAC4 | |
| SCHEMBL2515885 | 0.86 | EPHX1 (0.67) | EPHX1USP30HDAC4HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590978-B1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY | FOB SYNTHESIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | CHOI, WOO-BAEG, DR. | 2015-10-29 | — | — | US | disclosed |
| US-9149461-B2 | Carbapenem antibacterials with gram-negative activity | FOB SYNTHESIS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130172313-A1 | Carbapenem Antibacterials with Gram-Negative Activity | FOB SYNTHESIS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2011160020-A2 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY | FOB SYNTHESIS (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1404338-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | HERLING ANDREAS (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-0912520-B1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6559313-B2 | Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002092093-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1258247-A1 | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | Aventis Pharma Deutschland GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-6441017-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6376472-B1 | N6-SUBSTITUTED ADENOSINES | AVENTIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | TPH1, TPH2, HTR1A | EPHX1 856/4885HSD11B1 204/4885CYP2C9 129/4885 |
| US-20130172313-A1 | Carbapenem Antibacterials with Gram-Negative Activity | MGAM, GSK3B, GSK3A | EPHX1 3387/4885HSD11B1 586/4885CYP2C9 2130/4885 |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | MGAM, GSK3B, GSK3A | EPHX1 3387/4885HSD11B1 586/4885CYP2C9 2130/4885 |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | IAPP, GPR119, INSR | EPHX1 1715/4885HSD11B1 101/4885CYP2C9 830/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | EPHX1 276/4885HSD11B1 258/4885CYP2C9 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.